Pneumococcal conjugate vaccine--a health priority

Area of Science:

• Pediatric infectious diseases
• Vaccinology
• Public health

Background:

• Pneumonia, particularly from Streptococcus pneumoniae, is a leading cause of childhood mortality globally.
• The HIV epidemic exacerbates the burden of pneumococcal pneumonia and invasive disease in children.
• Pneumococcal conjugate vaccine (PCV) is a critical intervention to mitigate these health challenges.

Purpose of the Study:

• To evaluate the effectiveness of PCV in reducing pneumococcal disease and mortality in children, including those with HIV.
• To assess the impact of PCV on antibiotic-resistant invasive pneumococcal disease.
• To highlight the need for increased PCV accessibility and prioritization in developing countries and for HIV-infected children.

Main Methods:

• Review of studies evaluating 9-valent PCV in South Africa and The Gambia.
• Analysis of PCV's impact on vaccine-serotype-specific invasive disease, antibiotic-resistant disease, and overall childhood mortality.
• Examination of PCV immunogenicity and efficacy in HIV-infected children compared to HIV-uninfected children.

Main Results:

• PCV demonstrated a 72-77% reduction in vaccine-serotype-specific invasive disease in vaccinated children.
• Vaccination with PCV led to a reduction in antimicrobial-resistant invasive disease.
• PCV reduced overall childhood mortality by 16% in The Gambia and showed significant benefits for HIV-infected children, despite lower efficacy.
• Indirect protection through herd immunity was observed, reducing disease burden in unvaccinated populations.

Conclusions:

• PCV is highly effective in reducing pneumococcal disease and mortality in children, with substantial benefits for HIV-infected populations.
• Despite concerns about serotype replacement, PCV has led to sustained reductions in invasive disease.
• Increased accessibility and prioritization of PCV, particularly for children in developing countries and those with HIV, are urgently needed.